EUVIMEDEUVIMED entdecken
Kohortenstudie

Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom

Nosheen Umar iD, Steven Wambua, Phil Harvey, Nicola J Adderley, Shamil Haroon, Nigel Trudgill

Inflammatory Bowel Diseases · 29.10.2026

DOI: 10.1093/ibd/izag218 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 29.10.2026. Verfasst von Nosheen Umar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sandwell and West Birmingham NHS Trust, West Bromwich, B71 4HJ, United Kingdom. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fecal calprotectin (FC) can help to differentiate inflammatory bowel disease (IBD) from other causes of lower gastrointestinal (GI) symptoms. This study aimed to study FC testing in primary care, associated factors, subsequent secondary care referrals and IBD diagnoses.

Methods

A retrospective cohort study was conducted using primary care data in England. Adults aged 18-60 with lower GI symptoms between 2015 and 2023 were included. FC testing 30 days before to 3 months after a recorded lower GI symptom was examined. A random-effects logistic regression model explored patient-level factors associated with FC testing. Referral pathways and diagnostic outcomes among patients with FC testing were examined.

Results

Of 830 936 symptomatic patients, 34 944 (4.2%) had FC testing. FC testing increased from 1.6% of symptomatic patients in 2015 to 7.7% in 2023 (P = .001). Factors negatively associated with FC testing included female sex (adjusted odds ratio [aOR], 0.80; 95% CI, 0.78-0.82), lower socioeconomic status (aOR, 0.90; 95% CI, 0.86-0.95), smoking (aOR, 0.86; 95% CI,, 0.83-0.89) and obesity (aOR, 0.92; 95% CI, 0.89-0.95). Among patients referred to gastroenterology, 23.7% with FC >250µg/g were diagnosed with IBD, but only 4.1% with FC 100-250µg/g. Among patients with rectal bleeding and FC 100-250µg/g, 9% had IBD. Despite normal FC results (<100µg/g), 25.2% of symptomatic patients were still referred to secondary care, of whom 0.5% were diagnosed with IBD and 1% with colorectal cancer.

Conclusion

FC can effectively triage primary care patients with suspected IBD. Despite negative FC results, a significant proportion of patients were still referred to secondary care, with very few diagnosed with IBD.

Schlagwörter

Stichwörter der Autor:innen

Faecal calprotectinInflammatory bowel diseasePrimary care

Autor:innen und Institutionen

  • Department of Gastroenterology, Sandwell and West Birmingham NHS Trust, West Bromwich, B71 4HJ, United Kingdom.
  • Department of Applied Health Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
  • Department of Gastroenterology, Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, United Kingdom.
  • National Institute for Health and Care Research Birmingham Biomedical Research Centre, Birmingham, B152TT, United Kingdom.
  • Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

ORCID-Profile: Nosheen Umar

Zitieren

APA

Umar, N., Wambua, S., Harvey, P., Adderley, N. J., Haroon, S., & Trudgill, N. (2026). Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag218

Vancouver

Umar N, Wambua S, Harvey P, Adderley NJ, Haroon S, Trudgill N. Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag218

BibTeX
@article{Umar2026,
  author = {Umar, Nosheen and Wambua, Steven and Harvey, Phil and Adderley, Nicola J and Haroon, Shamil and Trudgill, Nigel},
  title = {Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag218}
}
Kostenlos starten →